Introduction
endometrial cancer, gynecological malignancies
ENDOMETRIAL CANCER, ENDOMETRIAL CANCER, UTERINE NEOPLASMS, SECONDARY, GYNECOLOGIC NEOPLASM
Cervical and endometrial cancer represent a considerable number of gynecologic neoplasms in women worldwide, with about 604,000 new cases of cervical and 417,000 new cases of uterine neoplasms diagnosed in 2020 [Through the widespread use of conventional intensity-modulated radiation therapy techniques, treatment-related side effects caused by pelvic radiotherapy have been mitigated [The primary aim of this prospective APROVE (Adjuvant PROton therapy for cerVical and Endometrial cancer) phase II trial was to evaluate the clinical feasibility and safety of the use of postoperative pelvic proton beam therapy for women with gynecological malignancies and to assess the potential for the reduction in doses to the organs at risk. Here, we evaluated this translation into and impact on clinically detected effects on the secondary study endpoints (health-related quality of life (HQROL) outcomes and patient-reported symptoms).